166 related articles for article (PubMed ID: 14556188)
1. [Preclinical research of a new therapy for Gaucher's disease with F213I mutation].
Hou L; Kousaku O
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Oct; 20(5):381-4. PubMed ID: 14556188
[TBL] [Abstract][Full Text] [Related]
2. Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation).
Zimmer KP; le Coutre P; Aerts HM; Harzer K; Fukuda M; O'Brien JS; Naim HY
J Pathol; 1999 Aug; 188(4):407-14. PubMed ID: 10440752
[TBL] [Abstract][Full Text] [Related]
3. Gaucher's disease.
Patel AL; Shaikh WA; Khobragade AK; Soni HG; Joshi AS; Sahasrabudhe GS; Chole PV
J Assoc Physicians India; 2009 May; 57():410-1. PubMed ID: 19634291
[TBL] [Abstract][Full Text] [Related]
4. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
Shaaltiel Y; Bartfeld D; Hashmueli S; Baum G; Brill-Almon E; Galili G; Dym O; Boldin-Adamsky SA; Silman I; Sussman JL; Futerman AH; Aviezer D
Plant Biotechnol J; 2007 Sep; 5(5):579-90. PubMed ID: 17524049
[TBL] [Abstract][Full Text] [Related]
5. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
Atrian S; López-Viñas E; Gómez-Puertas P; Chabás A; Vilageliu L; Grinberg D
Proteins; 2008 Feb; 70(3):882-91. PubMed ID: 17803231
[TBL] [Abstract][Full Text] [Related]
6. [Molecular basis of treatment in Gaucher's disease].
Pocoví M
Med Clin (Barc); 2011 Sep; 137 Suppl 1():32-8. PubMed ID: 22230123
[TBL] [Abstract][Full Text] [Related]
7. Animal and cellular models of Gaucher's disease. I. Refractoriness of thio analogs of glucocerebroside to enzymatic hydrolysis.
Quirk JM; Weis AL; Shapiro D; Brady RO
Biotechnol Appl Biochem; 1986 Feb; 8(1):96-100. PubMed ID: 3828086
[TBL] [Abstract][Full Text] [Related]
8. Comparison of rates of hydrolysis of N-oleoyl and N-stearoyl glucocerebroside in patients with Gaucher's disease.
Peters SP; Aquino L; Naccarato WF; Gilbertson JR; Diven WF; Glew RH
Biochim Biophys Acta; 1979 Oct; 575(1):27-36. PubMed ID: 508779
[TBL] [Abstract][Full Text] [Related]
9. 2,3-di-O-tetradecyl-1-O-(beta-D-glucopyranosyl)-sn-glycerol is a substrate for human glucocerebrosidase.
Glew RH; Gopalan V; Hubbell CA; Devraj RV; Lawson RA; Diven WF; Mannock DA
Biochem J; 1991 Mar; 274 ( Pt 2)(Pt 2):557-63. PubMed ID: 1900989
[TBL] [Abstract][Full Text] [Related]
10. Gaucher disease: accurate identification of asymptomatic French-Canadian carrier using nonlabeled authentic sphingolipid substrate N-palmitoyl dihydroglucocerebroside.
Choy FY; Bouillon L; Laurin CA
Am J Med Genet; 1987 Aug; 27(4):895-905. PubMed ID: 3425599
[TBL] [Abstract][Full Text] [Related]
11. Type I Gaucher's disease with homozygous R463C mutation without neurological involvement.
Bolaman Z; Kadikoylu G; Levi E; Barutca S; Temucin K
Haematologia (Budap); 2002; 32(4):487-93. PubMed ID: 12803123
[TBL] [Abstract][Full Text] [Related]
12. Minos-insertion mutant of the Drosophila GBA gene homologue showed abnormal phenotypes of climbing ability, sleep and life span with accumulation of hydroxy-glucocerebroside.
Kawasaki H; Suzuki T; Ito K; Takahara T; Goto-Inoue N; Setou M; Sakata K; Ishida N
Gene; 2017 May; 614():49-55. PubMed ID: 28286087
[TBL] [Abstract][Full Text] [Related]
13. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
[TBL] [Abstract][Full Text] [Related]
14. [Glucocerebrosidase deficiency--Gaucher's disease].
Tsuji S
Tanpakushitsu Kakusan Koso; 1988 Apr; 33(5):728-33. PubMed ID: 2908399
[No Abstract] [Full Text] [Related]
15. [Gaucher's disease and enzyme replacement therapy].
Cornu F
Ann Pharm Fr; 1998; 56(3):102-7. PubMed ID: 9770016
[TBL] [Abstract][Full Text] [Related]
16. Gaucher disease.
Butters TD
Curr Opin Chem Biol; 2007 Aug; 11(4):412-8. PubMed ID: 17644022
[TBL] [Abstract][Full Text] [Related]
17. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.
van Weely S; van den Berg M; Barranger JA; Sa Miranda MC; Tager JM; Aerts JM
J Clin Invest; 1993 Mar; 91(3):1167-75. PubMed ID: 8450045
[TBL] [Abstract][Full Text] [Related]
18. Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease.
Schmitz M; Alfalah M; Aerts JM; Naim HY; Zimmer KP
Int J Biochem Cell Biol; 2005 Nov; 37(11):2310-20. PubMed ID: 15982918
[TBL] [Abstract][Full Text] [Related]
19. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.
Ron I; Horowitz M
Hum Mol Genet; 2005 Aug; 14(16):2387-98. PubMed ID: 16000318
[TBL] [Abstract][Full Text] [Related]
20. Isozymes of beta-glucosidase: determination of Gaucher's disease phenotypes.
Ginns EI; Erickson A; Tegelaers FP; Barneveld R; Reuser AJ; Brady RO; Tager JM; Barranger JA
Isozymes Curr Top Biol Med Res; 1983; 11():83-93. PubMed ID: 6417048
[No Abstract] [Full Text] [Related]
[Next] [New Search]
